XML 53 R56.htm IDEA: XBRL DOCUMENT v3.3.0.814
Offsetting Assets and Liabilities (Tables)
9 Months Ended
Sep. 30, 2015
Offsetting [Abstract]  
Offsetting Assets and Liabilities [Table Text Block]
The composition of offsetting derivative instruments, financial assets, and financial liabilities was as follows.
 
 
Gross Amounts of Recognized Assets/(Liabilities)
 
Gross Amounts Offset in the Condensed Consolidated Balance Sheet
 
Net Amounts of Assets/(Liabilities)
Presented in the
Condensed Consolidated Balance Sheet
 
 
 
 
 
 
 
 
 
 
 
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet
 
 
September 30, 2015 ($ in millions)
 
 
 
 
Financial Instruments
 
Collateral
 (a) (b) (c)
 
Net Amount
Assets
 
 
 
 
 
 
 
 
 
 
 
 
Derivative assets in net asset positions
 
$
298

 
$

 
$
298

 
$
(114
)
 
$
(122
)
 
$
62

Derivative assets in net liability positions
 
1

 

 
1

 
(1
)
 

 

Total assets (d)
 
$
299


$


$
299


$
(115
)

$
(122
)

$
62

Liabilities
 
 
 
 
 
 
 
 
 
 
 
 
Derivative liabilities in net liability positions
 
$
(54
)
 
$

 
$
(54
)
 
$
1

 
$
11

 
$
(42
)
Derivative liabilities in net asset positions
 
(114
)
 

 
(114
)
 
114

 

 

Derivative liabilities with no offsetting arrangements
 
(8
)
 

 
(8
)
 

 

 
(8
)
Total derivative liabilities (d)
 
(176
)
 

 
(176
)
 
115

 
11

 
(50
)
Securities sold under agreements to repurchase (e)
 
(1,520
)
 

 
(1,520
)
 

 
1,520

 

Total liabilities
 
$
(1,696
)
 
$

 
$
(1,696
)
 
$
115

 
$
1,531

 
$
(50
)
(a)
Financial collateral received/pledged shown as a balance based on the sum of all net asset and liability positions between Ally and each individual derivative counterparty.
(b)
Amounts disclosed are limited to the financial asset or liability balance and, accordingly, exclude excess collateral received or pledged and non-cash collateral received. $8 million of non-cash derivative collateral pledged to us was excluded at September 30, 2015. We do not record such collateral received on our Condensed Consolidated Balance Sheet unless certain conditions are met.
(c)
Certain agreements grant us the right to sell or pledge the non-cash assets we receive as collateral. Non-cash collateral pledged to us where the agreement grants us the right to sell or pledge the underlying assets had a fair value of $8 million at September 30, 2015. We have not sold or pledged any of the non-cash collateral received under these agreements as of September 30, 2015.
(d)
For additional information on derivative instruments and hedging activities, refer to Note 20.
(e)
For additional information on securities sold under agreements to repurchase, refer to Note 13.
 
 
Gross Amounts of Recognized Assets/(Liabilities)
 
Gross Amounts Offset in the
Condensed Consolidated Balance Sheet
 
Net Amounts of Assets/(Liabilities)
Presented in the
Condensed Consolidated Balance Sheet
 
 
 
 
 
 
 
 
 
 
 
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet
 
 
December 31, 2014 ($ in millions)
 
 
 
 
Financial Instruments
 
Collateral (a)
 
Net Amount
Assets
 
 
 
 
 
 
 
 
 
 
 
 
Derivative assets in net asset positions
 
$
216

 
$

 
$
216

 
$
(60
)
 
$
(68
)
 
$
88

Derivative assets in net liability positions
 
47

 

 
47

 
(47
)
 

 

Total assets (b)
 
$
263

 
$

 
$
263

 
$
(107
)
 
$
(68
)
 
$
88

Liabilities
 
 
 
 
 
 
 
 
 
 
 
 
Derivative liabilities in net liability positions
 
$
(188
)
 
$

 
$
(188
)
 
$
47

 
$
54

 
$
(87
)
Derivative liabilities in net asset positions
 
(60
)
 

 
(60
)
 
60

 

 

Derivative liabilities with no offsetting arrangements
 
(4
)
 

 
(4
)
 

 

 
(4
)
Total derivative liabilities (b)
 
(252
)
 

 
(252
)
 
107

 
54

 
(91
)
Securities sold under agreements to repurchase (c)
 
(774
)
 

 
(774
)
 

 
774

 

Total liabilities
 
$
(1,026
)
 
$

 
$
(1,026
)
 
$
107

 
$
828

 
$
(91
)
(a)
Financial collateral received/pledged shown as a balance based on the sum of all net asset and liability positions between Ally and each individual derivative counterparty.
(b)
For additional information on derivative instruments and hedging activities, refer to Note 20.
(c)
For additional information on securities sold under agreements to repurchase, refer to Note 13